Cambrex Corporation has approved a USD 26 million expansion of its GMP contract bioprocessing capacity. The investment consists of two projects to support manufacturing of clinical trial quantities and licensed products. The first project will add mammalian cell culture capabilities to the Cambrex Bio Science, Baltimore, Maryland facility and is expected to cost USD 18.5 million. The second project will increase fermentation capacity at the Cambrex Bio Science, Hopkinton, Massachusetts facility and is expected to cost USD 7.7 million. The Baltimore expansion is expected to take approximately two years to complete and will add two cell propagation and purification suites and central support areas to be built in a facility adjacent to the current site. Phase I will include a 3000-litre stir tank and 500-litre perfusion reactor for new cell culture business. This first phase of the project will increase the existing capacity of the site from approximately 3300 litres to 6300 litres. Client projects are expected to begin in mid-2004. Phase II will include a second suite to operate either mammalian cell culture or fermentation processes at a 3000 to 5000 litre capacity. The Hopkinton expansion is expected to take approximately 18 months and will add one 3000-litre fermentation and purification process suite built within the footprint of the existing building. Validation is targeted for completion by the end of the first quarter of 2004.
Looking for more projects or tenders? Subscribe to our Project Preview Newsletter
